Why Metabolic Dysfunction Keeps HS Inflamed
Insulin resistance does not cause HS on its own. But in many patients — particularly those whose HS is worsening, recurring despite treatment, or linked to weight, hormonal imbalance, or PCOS — metabolic dysfunction is a central and often overlooked driver of the internal environment in which HS persists.
Understanding the insulin–HS connection explains why the condition so frequently coexists with other metabolic conditions, why dietary changes can meaningfully affect lesion frequency, and why addressing metabolic health is a clinical necessity — not a lifestyle suggestion — in these cases.
How Insulin Resistance Drives HS — Step by Step
AyurvedaMeda Dushti · ApatharpanaThe connection between insulin resistance and HS is not superficial. It operates through multiple intersecting pathways — hormonal, inflammatory, and structural — each of which amplifies the core process that sustains HS lesion formation.
Elevated Insulin Drives Androgen Excess
When cells resist insulin's signalling, the pancreas compensates with higher circulating insulin levels. Elevated insulin directly stimulates the ovaries and adrenal glands to produce more androgens — the same androgen excess that drives sebaceous gland hyperactivity, follicular keratinisation, and the follicular occlusion that initiates HS lesions. This is the central pathway linking insulin resistance to hormonal HS — and explains why the two so frequently coexist.
Chronic Low-Grade Systemic Inflammation
Insulin resistance is not metabolically neutral — it generates a sustained state of low-grade systemic inflammation through multiple pathways, including increased production of pro-inflammatory cytokines (particularly TNF-α and IL-6) and impaired anti-inflammatory signalling. This background inflammatory state is the same environment that sustains HS activity between visible flares — which is why patients with significant insulin resistance tend to experience more frequent recurrences and less complete resolution between episodes.
IGF-1 Amplifies Follicular Dysfunction
Elevated insulin raises insulin-like growth factor 1 (IGF-1), which further amplifies androgen activity and promotes abnormal follicular keratinocyte proliferation — the cellular process that leads to follicular plugging. IGF-1 also suppresses the proteins that normally keep androgens in an inactive, bound form, effectively increasing the amount of active androgen available to stimulate the follicular units most susceptible to HS.
Impaired Immune Resolution
Insulin resistance disrupts the normal immune resolution process — the mechanism by which inflammation clears and tissue begins to repair after a stimulus. In insulin-resistant individuals, inflammatory responses tend to be prolonged and less effectively resolved, meaning each HS episode takes longer to settle, tissue damage accumulates more rapidly, and the interval between episodes shortens progressively as metabolic dysfunction deepens.
Adipose Tissue as an Inflammatory Amplifier
Fat tissue — particularly visceral fat — is metabolically active. In insulin-resistant individuals, adipose tissue itself produces inflammatory cytokines and oestrogen-converting enzymes that further alter the hormonal environment sustaining HS. This creates a reinforcing loop: metabolic dysfunction worsens HS, the chronic pain and reduced mobility of HS compound metabolic factors, and the cycle deepens without metabolic correction.
Who This Applies To — and How It Presents
Insulin resistance as an HS driver is most clinically relevant in specific patient patterns. Recognising which profile applies helps clarify what internal correction must prioritise.
HS with PCOS
The most direct overlap. PCOS is itself driven largely by insulin resistance — which produces the androgen excess underlying both PCOS symptoms and HS follicular dysfunction. Women with PCOS-linked HS typically experience cyclical flare patterns, clear hormonal triggers, and HS that worsens during periods of increased metabolic stress such as weight gain or high-carbohydrate dietary periods.
HS with Central Obesity
Visceral fat accumulation is both a marker of and a contributor to insulin resistance. Patients with central obesity and HS frequently have higher flare frequency, more lesions simultaneously active, and slower resolution between episodes — reflecting the combined effect of mechanical factors (friction, occlusion) and the metabolic amplification of the internal inflammatory environment.
HS That Worsens With Diet
Patients who notice clear flare patterns following high-glycaemic dietary periods — refined carbohydrates, sugar, processed foods — are often observing the insulin response in real time. The post-meal insulin spike amplifies the inflammatory and androgen pathways described above, sometimes triggering or worsening a lesion cycle within 24–72 hours of dietary excess.
Metabolic Dysfunction as Digestive and Tissue Disorder
From an Ayurvedic perspective, insulin resistance maps closely to the concept of impaired metabolic fire (Agni) combined with excess and dysfunctional fat tissue (Meda Dhatu). When the body's metabolic function is compromised, the digestive and transformative processes that should convert nutrients into functional tissue are disrupted — leading to accumulation of unprocessed metabolic waste that circulates as a systemic inflammatory burden.
This aligns with the modern understanding of insulin resistance as a state in which cellular metabolism is impaired across multiple organ systems simultaneously — not just a single organ problem. The Ayurvedic model of treating this as a whole-system metabolic correction, rather than targeting isolated symptoms, reflects the same logic as addressing insulin resistance as a systemic driver rather than managing its downstream effects individually.
"When the internal metabolic environment is dysregulated, the downstream consequences — including HS lesion activity — tend to persist regardless of what is applied externally."
What Metabolic Correction Means in Practice
Addressing insulin resistance as a driver of HS does not mean treating a separate condition alongside HS. It means recognising that the same internal environment sustaining the metabolic dysfunction is sustaining the inflammatory and hormonal conditions that drive lesion formation.
This integration changes both what treatment targets and how results are measured. Patients often notice that as metabolic function improves — reflected in more stable energy, reduced cravings, hormonal regularisation — lesion frequency begins to reduce in parallel. This is not coincidence: the same internal correction that supports metabolic function also reduces the androgen and inflammatory signalling that sustains HS.
The EPOH approach treats this as a unified system — not as parallel conditions requiring separate management — which is why the same personalised treatment framework addresses gut function, hormonal balance, inflammatory load, and metabolic correction as interconnected aspects of one systemic process.
What Addressing Insulin Resistance in HS Actually Involves
Correcting insulin resistance as an HS driver is not about generic lifestyle changes. It requires a structured, phased approach that addresses the metabolic dysfunction alongside — not separate from — the inflammatory and hormonal correction that HS requires.
Why Isolated Dietary Changes Are Insufficient Alone
Many patients with metabolic HS make dietary changes that produce temporary improvement — reduced lesion frequency during periods of strict adherence — but see recurrence return when dietary discipline lapses or stress increases. This pattern reflects the fact that dietary changes address the input side of the metabolic equation without correcting the internal dysfunction that makes the system insulin-resistant in the first place.
Sustained metabolic correction in HS requires addressing gut function (which directly affects insulin sensitivity through microbiome and inflammatory pathways), hormonal regulation (particularly the adrenal and ovarian androgen axes), and the systemic inflammatory environment that both causes and is amplified by insulin resistance — all in a structured sequence.
Gut restoration — Correcting the dysbiosis and impaired intestinal barrier function that drives systemic inflammation and directly impairs insulin sensitivity through endotoxin-mediated pathways
Inflammatory load reduction — Removing the chronic inflammatory burden that maintains insulin resistance at the cellular level, regardless of dietary input
Hormonal recalibration — Specifically addressing the androgen excess driven by elevated insulin through targeted endocrine support, not general hormone management
Metabolic stabilisation — Supporting the cellular metabolic function that determines how glucose and insulin are processed, reducing the downstream androgen and inflammatory amplification
Lifestyle integration — Structured dietary and movement guidance that supports — not replaces — the internal metabolic correction, making the changes sustainable rather than dependent on willpower alone
Understand the Full Metabolic Picture
Insulin resistance does not act in isolation. It connects to the hormonal, gut, and immune drivers of HS — and understanding each layer helps clarify how they reinforce one another.
If HS Keeps Recurring Despite Treatment, Metabolic Drivers May Be Sustaining It
Insulin resistance, when present, is not a background condition — it is an active amplifier of the hormonal and inflammatory processes that sustain HS. A personalised evaluation identifies whether metabolic dysfunction is contributing to your specific pattern, and maps how internal correction can address it alongside the broader HS treatment framework.